Please use this identifier to cite or link to this item:
|Title:||Discrepancies in Biotechnology/Chemical Patenting|
|Authors:||Zekos, Georgios I|
|Keywords:||Chemical patenting;biotechnology patents;written description;best mode requirement|
|Abstract:||The patent system is meant to protect technology—actual machines, devices, and new chemical compositions—rather than pure concepts. Without patents, enterprises that do not make the research and development investment needed to invent new medicines could directly copy the drug and challenge the innovator’s price, making it unfeasible for the innovator to generate funds to invest in discovering new medicines. Hence, the whole patenting process should not be prohibitive for companies but also should not accept loose principles allowing discrepancy to standards against consumers’ protection in order to allow companies to have undue profits. Biotechnology and chemistry inventions should have the same high written description standard injecting some reasonableness into the written description requirement in these regards. The main aim of the analysis is to investigate the existence of discrepancies in the standards between chemical and biotechnology patenting. The discrepancies between chemical and biotechnology patenting must be diminished in order to avoid double standards and so establishing predictability adding to the inventive prospects of firms.|
|Appears in Collections:||JIPR Vol.10(4) [July 2005]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.